Endo Announces South African Competition Act Compliance and Approval Under the Investment Canada Act in Connection with Its

Endo Announces South African Competition Act Compliance and Approval Under the
 Investment Canada Act in Connection with Its Proposed Acquisition of Paladin
                                     Labs

PR Newswire

MALVERN, Pa., Feb. 18, 2014

MALVERN, Pa., Feb. 18, 2014 /PRNewswire/ --Endo Health Solutions (Nasdaq:
ENDP) today announced that the South African Competition Commission has
completed its review and approved the merger of Endo and Paladin Labs without
conditions in terms of section 14(1)(b) of the Competition Act (South Africa).

In addition, the company announced that it has received regulatory approval
under the Investment Canada Act. The Minister of Industry has completed a
review of the transaction and determined that it is likely to produce a "net
benefit" to Canada.

As previously announced on November 5, 2013, Endo and Paladin entered into a
definitive agreement pursuant to which Endo would acquire Paladin Labs in a
stock and cash transaction valued at approximately $1.6 billion.

Today's announced approvals satisfy certain regulatory conditions to the
proposed acquisition. The proposed acquisition remains subject to certain
other conditions and approvals, including approval by shareholders of Endo and
Paladin Labs, approval of the Superior Court of Quebec, registration and
listing of New Endo shares and customary closing conditions.

About Endo
Endo Health Solutions Inc. is a U.S.-based specialty healthcare company with
business segments that are focused on branded pharmaceuticals, generics, and
medical devices which deliver quality products to its customers intended to
improve the lives of patients. Through its operating companies - Endo
Pharmaceuticals, Qualitest, and AMS - Endo is dedicated to delivering value to
our stakeholders: customers, patients, and shareholders. Learn more at
www.endo.com.

SOURCE Endo Health Solutions

Website: http://www.endo.com
Contact: Investors/Media: Blaine Davis, (484) 216-7158; Investors: Jonathan
Neely, (484) 216-6645; Media: Brian O'Donnell, (484) 216-6726
 
Press spacebar to pause and continue. Press esc to stop.